Manhattan Scientifics Delivers Fuel Cell Unit To U.S. Army

February 9, 2004

Click here to view the printer friendly version of this press release


New York, NY - February 9, 2004 - Manhattan Scientifics, Inc. (MHTX) announced today that it has delivered a 700-watt NovArs prototype fuel cell system to the U.S. Army under a contract received in the third quarter of last year. The contract was awarded as part of the Army's Communications-Electronics Command's (CECOM) competitive Foreign Technology Evaluation Program.

Manhattan Scientifics' management said the unit is being evaluated by CECOM with other units as a possible battery charger for tactical units.

A prototype NovArs fuel cell unit of the type being evaluated by the Department of Defense Fuel Cell Test and Evaluation Center (FCTec) was featured in several fuel cell publications and showcased at a recent fuel cell conference in Florida. A copy of the article can be accessed by visiting the MHTX website at

Manhattan Scientifics' COO Jack Harrod said, "We are pleased that the Department of Defense is testing our NovArs fuel cell technology. It is too early to speculate on the long term implications of this activity.

About Manhattan Scientifics

Manhattan Scientifics, Inc. ( is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.